Sanofi’s BLA for Praluent injection accepted in the USA
Sanofi and Regeneron has gotten the approval from the U.S. Food and Drug Administration (FDA) for Biologics License Application (sBLA) for Praluent Injection, a PCSK9 inhibitor.
Read more
news
Foamix Pharma Releases positive phase 3 acne data; stock soars 50% in after hours
Foamix Pharmaceuticals showed its topline results of its third Phase 3 clinical trial (FX2017-22) of FMX101 for the treatment of moderate-to-severe acne.
Read moreKaruna gets $42 million in financing round
PureTech Health and its affiliate Karuna have completed a $42 million Series A financing round, which will be used to
Read more
Amryt’s Epidermolysis Bullosa treatment granted Rare Pediatric Disease from US FDA
Amryt ensure US Food and Drug Administration’s grant a Rare Pediatric Disease designation for its lead development asset AP101, for
Read more
Sanofi net income €762M in second quarter
Sanofi reported €762m of net income in the second quarter 2018, after net sales of €8,176 million, down 5.7% on a
Read more
Single bacterial strains from the human gut microbiota can serve as HDAC inhibitors
4D pharma showed that specific single bacterial strains from the human gut microbiota can serve as therapeutic inhibitors of the
Read more
Beximco’s fifth ANDA approved in USA
Beximco Pharmaceuticals got approval from the US Food and Drug Administration (FDA), for its Nadolol tablets, a generic equivalent of Bristol-Myers Squibb’s
Read moreApricus Biosciences merges with Seelos Therapeutics
Apricus Biosciences will merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, in an all-stock transaction, it announced on Monday,
Read more
Positive data supports product opportunities for XF-73 in dermal infection indications
Destiny Pharma’s first of two Phase 1 safety clinical studies of testing XF-73’s potential to cause dermal irritation, as Destiny’s
Read more
Neurodegeneration may be tied to drainage issues in the brain
PureTech Health’s new internal programme focused on treating central nervous system (CNS) disorders via modulation of the brain’s lymphatic system,
Read more